Hagens Berman has opened an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand related to possible false claims and kickbacks involving its heart failure device, Barostim. The company also cut its 2026 revenue guidance sharply due to sales force problems and a collapse in Medicare Advantage approvals, causing its stock to drop 59%. The sudden firing of CVRx's Chief Revenue Officer shortly after these disclosures raises questions about internal issues and potential investor misinformation. Investors who suffered losses are encouraged to evaluate their legal options.
Constellation Energy, a leading nuclear power producer, has increased its full-year 2026 earnings guidance to $12 per share, up 28% from last year. Despite a recent analyst price target cut and a broader market sell-off influenced by AI investment co...
Marti Technologies reported a 141% revenue increase to nearly $20 million in Q2 2026, beating analyst expectations driven by subscription monetization and higher trip volumes. Despite this strong growth, the company posted a loss of $0.15 per share, ...
Workday has established a dedicated AI Research team to develop advanced, reliable AI solutions for enterprises, achieving notable improvements in AI memory precision and task accuracy. The company also introduced a PhD Fellowship program to support ...
Telsey Advisory Group raised Abercrombie & Fitch's price target from $115 to $118, implying an 11.35% upside from the current share price of around $106. Meanwhile, Raymond James downgraded the stock from "Outperform" to "Market Perform," signaling e...
Barclays maintained an "Underweight" rating on Target's stock but raised its price target from $115 to $140, even though Target's shares trade above $161. This cautious stance reflects concerns that Target may underperform its peers despite a strong ...
